Table 4 Hazard Ratios by HPV-16 E6/E7 baseline status and change in OD ratio at last follow-up
Outcome/Antibody Status | HPV-16 E6 | HPV-16 E7 | HPV-16 E6 and/or E7 | ||||||
|---|---|---|---|---|---|---|---|---|---|
n (%) | HR (95% CI)1 | p-value2 | n (%) | HR (95% CI)1 | p-value2 | n (%) | HR (95% CI)1 | p-value2 | |
Overall Deaths | 0.01 | 0.04 | 0.01 | ||||||
Negative | 353 (40.2) | 4.6 (1.4-15.3) | 344 (38.2) | 3.0 (1.03-8.5) | 344 (41.0) | 3.8 (1.3-11.0) | |||
Positive | 3 (13.6) | 1.0 | 4 (20.0) | 1.0 | 4 (15.8) | 1.0 | |||
No OD decrease | 0 | 0 | 0 | ||||||
OD Decrease | 35 | 45 | 45 | ||||||
Disease Specific Deaths | 0.017 | 0.07 | 0.04 | ||||||
Negative | 196 (24.4) | NE3 | 188 (22.5) | 6.4 (0.8-48.7) | 188 (24.3) | 8.4 (1.1-63.3) | |||
Positive | 0 (0.0) | 1.0 | 1 (5.6) | 1.0 | 1 (4.2) | 1.0 | |||
No OD decrease | 0 | 0 | 0 | ||||||
OD Decrease | 0 | 15 | 15 | ||||||
Recurrence | 0.35 | 0.36 | 0.90 | ||||||
Negative | 178 (21.5) | 2.1 (0.4-9.7) | 174 (21.0) | 2.0 (0.4-9.4) | 159 (20.0) | 1.1 (0.3-3.5) | |||
Positive | 2 (9.1) | 1.0 | 2 (10.0) | 1.0 | 4 (15.4) | 1.0 | |||
No OD decrease | 15 | 0 | 25 | ||||||
OD Decrease | 1 | 210 | 210 | ||||||